Sr One Capital Management, Llc - Sep 16, 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
10%+ Owner
Signature
/s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC
Stock symbol
ZBIO
Transactions as of
Sep 16, 2024
Transactions value $
$37,999,998
Form type
4
Date filed
9/16/2024, 08:51 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZBIO Common Stock Conversion of derivative security +1.51M 1.51M Sep 16, 2024 See Note 2 F1, F2
transaction ZBIO Common Stock Purchase $7.5M +441K +29.31% $17.00 1.95M Sep 16, 2024 See Note 2 F2
transaction ZBIO Common Stock Conversion of derivative security +502K 502K Sep 16, 2024 See Note 3 F1, F3
transaction ZBIO Common Stock Purchase $23M +1.35M +269.62% $17.00 1.85M Sep 16, 2024 See Note 3 F3
transaction ZBIO Common Stock Conversion of derivative security +669K 669K Sep 16, 2024 See Note 4 F1, F4
transaction ZBIO Common Stock Purchase $7.5M +441K +65.94% $17.00 1.11M Sep 16, 2024 See Note 4 F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Series C Convertible Preferred Stock Conversion of derivative security -13.1M -100% 0 Sep 16, 2024 Common Stock 1.51M See Note 2 F1, F2
transaction ZBIO Series C Convertible Preferred Stock Conversion of derivative security -4.36M -100% 0 Sep 16, 2024 Common Stock 502K See Note 3 F1, F3
transaction ZBIO Series C Convertible Preferred Stock Conversion of derivative security -5.81M -100% 0 Sep 16, 2024 Common Stock 669K See Note 4 F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Partners II, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Partners II, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
F3 The reported securities are held directly by AMZL, LP. SR One Capital SMA Partners, LP is the general partner of AMZL, LP, and SR One Capital Management, LLC is the general partner of SR One Capital SMA Partners, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital SMA Partners, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
F4 The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP, and SR One Capital Management, LLC is the general partner of SR One Capital Opportunities Partners I, LP. Simeon George, M.D. is the managing member of SR One Capital Management, LLC. Each of SR One Capital Opportunities Partners I, LP, SR One Capital Management, LLC and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.